ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.77
-1.09%
US Tech 100
20,778.00
-0.69%
S&P 500
6,040.53
-0.50%
US Dollar vs CAD
1.45405
0.00%
Bitcoin
102,421.28
0.01%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Replimune Group Inc (REPL)

  7. Replimune Group Inc (REPL) News

REPL

Replimune (REPL)

Replimune Group Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REPL
DateTimeSourceHeadlineSymbolCompany
01/22/20254:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
01/21/20257:00AMGlobeNewswire Inc.Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced MelanomaNASDAQ:REPLReplimune Group Inc
01/17/20254:01PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
01/10/20253:01PMGlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
01/08/20257:00AMGlobeNewswire Inc.Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical TrialsNASDAQ:REPLReplimune Group Inc
12/23/20247:00AMGlobeNewswire Inc.Replimune to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:REPLReplimune Group Inc
12/20/20244:00PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
12/18/20248:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REPLReplimune Group Inc
12/16/20243:48PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REPLReplimune Group Inc
12/04/20247:30AMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:REPLReplimune Group Inc
11/27/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
11/26/20244:27PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:REPLReplimune Group Inc
11/26/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
11/25/202410:55PMGlobeNewswire Inc.Replimune Announces Pricing of Upsized Public OfferingNASDAQ:REPLReplimune Group Inc
11/25/20246:09AMGlobeNewswire Inc.Replimune Announces Proposed Public OfferingNASDAQ:REPLReplimune Group Inc
11/21/20244:26PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
11/21/20243:05PMGlobeNewswire Inc.Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval PathwayNASDAQ:REPLReplimune Group Inc
11/20/20248:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REPLReplimune Group Inc
11/20/20248:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REPLReplimune Group Inc
11/19/20244:16PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
11/14/20246:00AMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:REPLReplimune Group Inc
11/12/20247:16AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:REPLReplimune Group Inc
11/12/20247:00AMGlobeNewswire Inc.Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate UpdateNASDAQ:REPLReplimune Group Inc
11/09/202412:00PMGlobeNewswire Inc.Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)NASDAQ:REPLReplimune Group Inc
11/08/20243:01PMGlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
10/30/20248:15AMGlobeNewswire Inc.Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:REPLReplimune Group Inc
10/16/20244:15PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
10/09/20243:01PMGlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
10/01/20247:00AMGlobeNewswire Inc.Replimune to Present at Two Upcoming Investor ConferencesNASDAQ:REPLReplimune Group Inc
09/15/20248:45AMGlobeNewswire Inc.Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024NASDAQ:REPLReplimune Group Inc
 Showing the most relevant articles for your search:NASDAQ:REPL

Your Recent History

USOTC
IQST
iQSTEL (QX)
USOTC
UMAV
UAV Corpoation (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
HMBL
HUMBL (PK)
AMEX
SPY
SPDR S&P 500
USOTC
RNVA
Rennova Health (CE)
USOTC
AFFU
Affluence (PK)
USOTC
PSRU
Valiant Eagle (PK)
USOTC
DPLS
DarkPulse (PK)
USOTC
MGON
Megola (PK)
USOTC
RDAR
Raadr (PK)
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
GTCH
GBT Technologies (PK)
NASDAQ
COOP
Mr Cooper
USOTC
SPZI
Spooz (PK)
NASDAQ
AMRN
Amarin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads